Hematopoietic/Lymphoid Cancer Withdrawn Phase 1 / 2 Trials for Brentuximab vedotin (DB08870)

IndicationStatusPhase
DBCOND0030132 (Hematopoietic/Lymphoid Cancer)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01620229Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTreatment